Literature DB >> 17305479

Targeting of Jak/STAT pathway in antigen presenting cells in cancer.

Yulia Nefedova1, Dmitry I Gabrilovich.   

Abstract

One of the major mechanisms of tumor escape is the inability of antigen presenting cells (APC), and specifically the most potent APC dendritic cells (DC), to induce potent antitumor immune response. The defects in APC are caused by the variety of tumor-derived factors. In this review we will discuss recent findings which indicate that the members of the family of signal transducers and activators of transcription (STATs), and more specifically STAT3, could be responsible for the abnormal DC differentiation and function in cancer. The different approaches to pharmacological regulation of this pathway and their effects on DC function and antitumor immune responses will be discussed.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17305479     DOI: 10.2174/156800907780006887

Source DB:  PubMed          Journal:  Curr Cancer Drug Targets        ISSN: 1568-0096            Impact factor:   3.428


  19 in total

1.  Mesenchymal Stem Cells Overexpressing IFN-β Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model.

Authors:  Xiaoyang Ling; Frank Marini; Marina Konopleva; Wendy Schober; Yuexi Shi; Jared Burks; Karen Clise-Dwyer; Rui-Yu Wang; Weiguo Zhang; Xiaoqing Yuan; Hongbo Lu; Lisa Caldwell; Michael Andreeff
Journal:  Cancer Microenviron       Date:  2010-03-19

Review 2.  Negative regulation of myeloid-derived suppressor cells in cancer.

Authors:  Peng Qu; Kimberly C Boelte; P Charles Lin
Journal:  Immunol Invest       Date:  2012       Impact factor: 3.657

3.  Elucidation of the molecular mechanisms of a salicylhydrazide class of compounds by proteomic analysis.

Authors:  Xuefei Cao; Carmen Plasencia; Atsuko Kanzaki; Austin Yang; Terrence R Burke; Nouri Neamati
Journal:  Curr Cancer Drug Targets       Date:  2009-03       Impact factor: 3.428

4.  Mechanism regulating reactive oxygen species in tumor-induced myeloid-derived suppressor cells.

Authors:  Cesar A Corzo; Matthew J Cotter; Pingyan Cheng; Fendong Cheng; Sergei Kusmartsev; Eduardo Sotomayor; Tapan Padhya; Thomas V McCaffrey; Judith C McCaffrey; Dmitry I Gabrilovich
Journal:  J Immunol       Date:  2009-05-01       Impact factor: 5.422

5.  Cyclophilin D extramitochondrial signaling controls cell cycle progression and chemokine-directed cell motility.

Authors:  Michele Tavecchio; Sofia Lisanti; Aaron Lam; Jagadish C Ghosh; Nina M Martin; Michael O'Connell; Ashani T Weeraratna; Andrew V Kossenkov; Louise C Showe; Dario C Altieri
Journal:  J Biol Chem       Date:  2013-01-09       Impact factor: 5.157

Review 6.  The dendritic cell-regulatory T lymphocyte crosstalk contributes to tumor-induced tolerance.

Authors:  Nona Janikashvili; Bernard Bonnotte; Emmanuel Katsanis; Nicolas Larmonier
Journal:  Clin Dev Immunol       Date:  2011-11-03

Review 7.  Immunotherapy using dendritic cells against multiple myeloma: how to improve?

Authors:  Thanh-Nhan Nguyen-Pham; Yoon-Kyung Lee; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Clin Dev Immunol       Date:  2012-03-15

8.  Cellular immunotherapy using dendritic cells against multiple myeloma.

Authors:  Thanh-Nhan Nguyen-Pham; Youn-Kyung Lee; Hyun-Ju Lee; Mi-Hyun Kim; Deok-Hwan Yang; Hyeoung-Joon Kim; Je-Jung Lee
Journal:  Korean J Hematol       Date:  2012-03-28

9.  The induction of APC with a distinct tolerogenic phenotype via contact-dependent STAT3 activation.

Authors:  Devorah Gur-Wahnon; Zipora Borovsky; Meir Liebergall; Jacob Rachmilewitz
Journal:  PLoS One       Date:  2009-08-31       Impact factor: 3.240

10.  Novel mechanism of inhibition of dendritic cells maturation by mesenchymal stem cells via interleukin-10 and the JAK1/STAT3 signaling pathway.

Authors:  Wen-hua Liu; Jing-jin Liu; Jian Wu; Lu-lu Zhang; Fang Liu; Li Yin; Mao-mao Zhang; Bo Yu
Journal:  PLoS One       Date:  2013-01-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.